Spun out in 2007 by Oxford University Innovation, the company has commercialised technological breakthroughs in a new generation of biomarkers for cancer and other diseases.
Read more (Sir William Dunn School of Pathology website)
Clinical Trials Innovation Research
6 December 2016
Oxford Biodynamics, a biomarker company set up by former Dunn School researchers Dr Alexandre Akoulitchev and Dr Aroul Ramadass, completed a successful flotation on AIM, the London Stock Exchange’s international market for smaller growing companies, on 6 December 2016.